Prestige Consumer Healthcare (NYSE:PBH) Given New $104.00 Price Target at DA Davidson

Prestige Consumer Healthcare (NYSE:PBH) had its price objective increased by DA Davidson from $95.00 to $104.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

PBH has been the subject of several other reports. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Finally, StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $92.50.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $86.96 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. Prestige Consumer Healthcare has a 1 year low of $60.00 and a 1 year high of $88.36. The company has a market cap of $4.30 billion, a P/E ratio of 20.37, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50. The stock’s fifty day moving average price is $79.23 and its 200-day moving average price is $75.48.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last three months. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently bought and sold shares of the stock. HighTower Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 89.5% during the 4th quarter. HighTower Advisors LLC now owns 31,666 shares of the company’s stock valued at $2,473,000 after purchasing an additional 14,958 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Prestige Consumer Healthcare by 7.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,053 shares of the company’s stock valued at $863,000 after buying an additional 731 shares during the last quarter. Amundi grew its holdings in Prestige Consumer Healthcare by 187.4% during the 4th quarter. Amundi now owns 25,669 shares of the company’s stock valued at $1,909,000 after buying an additional 16,737 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Prestige Consumer Healthcare by 5.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,276 shares of the company’s stock worth $412,000 after acquiring an additional 296 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $42,593,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.